3963 Maple Avenue
Suite 350
Dallas, TX 75219
United States
972 499 3350
https://instilbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 49
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Bronson Crouch | Chairman & CEO | 672.37k | N/D | 1973 |
Dr. Sandeep Laumas M.D. | CFO & Chief Business Officer | 489.14k | N/D | 1969 |
Dr. Mark E. Dudley Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
Dr. Robert Hawkins MBBS, Ph.D. | Head of Research & Development | 218.72k | N/D | N/D |
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
La calificación ISS Governance QuickScore de Instil Bio, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 8; Compensación: 9.